ConocoPhillips vs Heron Therapeutics Inc — how do they compare? ConocoPhillips trades at $111.54 (market cap $137.48B), while Heron Therapeutics Inc trades at $0.46 (market cap $78.91M). The key difference: ConocoPhillips is far larger — about 1742.2× Heron Therapeutics Inc's market cap, and ConocoPhillips pays a 2.98% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| COP | HRTX | |
|---|---|---|
Market Cap | $137.48B | $78.91M |
Sector | Energy | Health |
52-Week High | $133.80 | $2.04 |
52-Week Low | $85.66 | $0.39 |
Enterprise Value | $154.45B | $176.81M |
Dividend Yield | 2.98% | — |
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $112.85, up 3.49% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q1 2026 earnings, beating EPS estimates but showing declining revenue and net income margins since 2022. Recent news highlights oil price volatility and geopolitical risks influencing energy stocks.
COP offers value with a P/E of 19.13 and bullish analyst targets averaging $137.14, but faces headwinds from falling profitability and oil market instability. Investment appeal hinges on execution amid volatile commodity prices and competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →